Preclinical activity of selinexor in combination with eribulin in uterine leiomyosarcoma.
Saved in:
| Title: | Preclinical activity of selinexor in combination with eribulin in uterine leiomyosarcoma. |
|---|---|
| Authors: | Mittal S; Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, WI, USA., Kadamberi IP; Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, WI, USA., Chang H; Karyopharm Therapeutics, Inc, Newton, MA, USA., Wang F; Karyopharm Therapeutics, Inc, Newton, MA, USA., Kumar S; Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, WI, USA., Tsaih SW; Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, WI, USA., Walker CJ; Karyopharm Therapeutics, Inc, Newton, MA, USA., Chaluvally-Raghavan P; Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, WI, USA.; Medical College of Wisconsin-Cancer Center, Milwaukee, WI, USA.; Department of Physiology, Medical College of Wisconsin, Milwaukee, WI, USA., Charlson J; Medical Oncology, Medical College of Wisconsin, Milwaukee, WI, 53226, USA., Landesman Y; Karyopharm Therapeutics, Inc, Newton, MA, USA., Pradeep S; Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, WI, USA. spradeep@mcw.edu.; Medical College of Wisconsin-Cancer Center, Milwaukee, WI, USA. spradeep@mcw.edu.; Department of Physiology, Medical College of Wisconsin, Milwaukee, WI, USA. spradeep@mcw.edu. |
| Source: | Experimental hematology & oncology [Exp Hematol Oncol] 2023 Sep 15; Vol. 12 (1), pp. 78. Date of Electronic Publication: 2023 Sep 15. |
| Publication Type: | Letter |
| Journal Info: | Publisher: BioMed Central Country of Publication: England NLM ID: 101590676 Publication Model: Electronic Cited Medium: Print ISSN: 2162-3619 (Print) Linking ISSN: 21623619 NLM ISO Abbreviation: Exp Hematol Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
